Antiretroviral compounds and cholesterol efflux from macrophages
- 9 April 2009
- journal article
- research article
- Published by Elsevier in Atherosclerosis
- Vol. 206 (2) , 439-443
- https://doi.org/10.1016/j.atherosclerosis.2009.02.042
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- HIV infection and high density lipoprotein metabolismAtherosclerosis, 2007
- How HIV protease inhibitors promote atherosclerotic lesion formationCurrent Opinion in Lipidology, 2007
- Human Immunodeficiency Virus Protease Inhibitor Ritonavir Inhibits Cholesterol Efflux from Human Macrophage-Derived Foam CellsThe American Journal of Pathology, 2007
- Class of Antiretroviral Drugs and the Risk of Myocardial InfarctionNew England Journal of Medicine, 2007
- HIV and Cardiovascular Disease: Contribution of HIV-Infected Macrophages to Development of AtherosclerosisPLoS Medicine, 2007
- In Vitro Cytotoxicity and Mitochondrial Toxicity of Tenofovir Alone and in Combination with Other Antiretrovirals in Human Renal Proximal Tubule CellsAntimicrobial Agents and Chemotherapy, 2006
- Human Immunodeficiency Virus Impairs Reverse Cholesterol Transport from MacrophagesPLoS Biology, 2006
- Premature atherosclerosis in HIV positive patients and cumulated time of exposure to antiretroviral therapy (SHIVA study)Atherosclerosis, 2006
- Cardiovascular Risk in Patients with HIV InfectionDrugs, 2006
- Demethylation using the epigenetic modifier, 5-azacytidine, increases the efficiency of transient transfection of macrophagesJournal of Lipid Research, 2005